Expert discusses FDA pooled analyses in lung cancer

June 21, 2022

1 min watch



Healio Interviews

Akinboro O, et al. Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50 %: FDA pooled analysis. Presented at: ASCO Annual meeting; June 3-7, 2022; Chicago.

Nakajima EC, et al. Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis. Presented at: ASCO Annual meeting; June 3-7, 2022; Chicago.

Disclosures: Marmarelis reports holding stock and other ownership interests in Bluebird Bio, Gilead Sciences; Johnson & Johnson, Merck, Pfizer, and Portola Pharmaceuticals; receiving honoraria from AstraZeneca, Blueprint Medicines, Health Advances, Janssen Oncology, Novocure, Takeda, and Targeted Oncology; serving in a consulting or advisory role for AstraZeneca Boehringer Ingelheim, Bristol-Myers Squibb/Celgene, and Ikena Oncology; receiving research funding to Marmarelis’s institution from AstraZeneca, Lilly, and Trizell; receiving travel, accommodations and expenses from Boehringer Ingelheim and Novocure; and having another relationship with Novartis.

We were unable to process your request. Please try again later. If you continue to have this issue please contact

In this video, Melina MarmarelisMD, discussed results from two FDA pooled analyses in lung cancer that were presented at the ASCO annual meeting.

“We need better indicators for what is high-risk disease in order to choose patients who could benefit from chemotherapy because clearly there’s a population that can really benefit from chemotherapy, even in the high PD-L1 group,” Marmarelis, assistant professor of medicine at the University of Pennsylvania, said.

Leave a Reply

Your email address will not be published.